NGENF
Price:
$2.17
Market Cap:
$218.66M
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.[Read more]
Industry
Biotechnology
IPO Date
2019-04-03
Stock Exchange
PNK
Ticker
NGENF
According to NervGen Pharma Corp.’s latest financial reports and current stock price. The company's current ROE is -249.04%. This represents a change of -435.80% compared to the average of 74.16% of the last 4 quarters.
The mean historical ROE of NervGen Pharma Corp. over the last ten years is 85.15%. The current -249.04% ROE has changed -392.47% with respect to the historical average. Over the past ten years (40 quarters), NGENF's ROE was at its highest in in the December 2023 quarter at 428.47%. The ROE was at its lowest in in the September 2023 quarter at -84.24%.
Average
85.15%
Median
-75.17%
Minimum
-188.78%
Maximum
1.11%
Discovering the peaks and valleys of NervGen Pharma Corp. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 206.28%
Maximum Annual ROE = 1.11%
Minimum Annual Increase = -928.22%
Minimum Annual ROE = -188.78%
Year | ROE | Change |
---|---|---|
2023 | 1.11% | -928.22% |
2022 | -134.51% | 78.94% |
2021 | -75.17% | -60.18% |
2020 | -188.78% | 14.08% |
2019 | -165.48% | 206.28% |
2018 | -54.03% | -154.03% |
The current ROE of NervGen Pharma Corp. (NGENF) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
301.45%
5-year avg
110.02%
10-year avg
85.15%
NervGen Pharma Corp.’s ROE is
Company | ROE | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NervGen Pharma Corp. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like NervGen Pharma Corp. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is NervGen Pharma Corp.'s ROE?
How is the ROE calculated for NervGen Pharma Corp. (NGENF)?
What is the highest ROE for NervGen Pharma Corp. (NGENF)?
What is the 3-year average ROE for NervGen Pharma Corp. (NGENF)?
What is the 5-year average ROE for NervGen Pharma Corp. (NGENF)?
How does the current ROE for NervGen Pharma Corp. (NGENF) compare to its historical average?